Toxicity, recurrence and survival after adjuvant radiotherapy treatment for FIGO stage I cancer of the endometrium

被引:3
|
作者
Moss, EL
Stevens, A
Gray, L
McConkey, C
Fernando, I
机构
[1] Univ Hosp, Dept Clin Oncol, Birmingham, W Midlands, England
[2] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
关键词
adjuvant radiotherapy; vaginal vault brachytherapy; endometrial cancer; recurrence; survival; toxicity;
D O I
10.1016/S0936-6555(03)00149-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We conducted a retrospective observational study to determine the rate of toxicity, pattern of tumour recurrence and survival associated with radiotherapy treatment for FIGO stage I cancer of the endometrium. All patients had undergone definitive surgery and had been referred to the oncology department of the University Hospital Birmingham, U.K. Two hundred and forty-five women were included in the study; 228 patients were treated with radiotherapy; 160 had external beam radiation alone; 32 had vaginal vault brachytherapy alone; 36 patients had both modalities; and 17 patients were not given radiotherapy. There were nine cases of Grade 3 and 4 radiation reactions, of which four were acute, four were late and one was acute and late toxicity. The severity of both acute and late radiation effects was significantly associated with the delivery of vault brachytherapy (external beam radiotherapy alone compared with brachytherapy alone (1/158 vs 3/32; P=0.02). Thirty-four patients were diagnosed with tumour recurrence (11 distant, 14 local, 4 patients had both distant and local disease and 5 patients had recurrence diagnosed at the time of death). Patients who received no radiotherapy were at greater risk of local pelvic tumour recurrence (P<0.0001; hazard ratio [HR] 9.6, 95% confidence interval (CI) 3.5-26.3). Vaginal vault brachytherapy had no discernible effect on the pattern of tumour recurrence. Forty-six patients died during the follow-up period, 28 of these were attributable to carcinoma of the endometrium. There was no difference in survival between the four treatment groups (P=0.68). The overall 5-year survival rate in our study group was 89.6% (85.4-93.8%). In a proportional hazards model, tumour grade (HR 2.0 per level [1.25, 3.17]; P=0.004]) and age (HR 1.74 per 10 years [1.12, 2.69]; P=0.01) were the only factors found to have an independent influence on survival. This study suggests that, although pelvic radiation may not alter overall survival, it does reduce the risk of local disease recurrence. In this study population, vaginal vault brachytherapy using a vaginal stock/dobbie showed no additional benefits compared with external beam radiotherapy; it was, however, associated with a higher rate of both acute and late radiation effects. (C) 2003 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 50 条
  • [21] THE EFFECT OF ADJUVANT CHEMOTHERAPY ON SURVIVAL IN PATIENTS WITH FIGO STAGE I HIGH-GRADE SEROUS OVARIAN CANCER
    van Baal, J.
    Van de Vijver, K.
    van der Aa, M.
    Sonke, G.
    van Driel, W.
    Kenter, G.
    Amant, F.
    Lok, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 756 - 757
  • [22] The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
    van Baal, J.
    Van de Vijver, K.
    Algera, M.
    van der Aa, M.
    Sonke, G.
    van Driel, W.
    Kenter, G.
    Amant, F.
    Lok, C.
    VIRCHOWS ARCHIV, 2019, 475 : S88 - S88
  • [23] Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer
    Mabuchi, Seiji
    Okazawa, Mika
    Isohashi, Fumiaki
    Matsuo, Koji
    Ohta, Yukinobu
    Suzuki, Osamu
    Yoshioka, Yasuo
    Enomoto, Takayuki
    Kamiura, Shoji
    Kimura, Tadashi
    GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 241 - 247
  • [24] The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer
    van Baal, J. O. A. M.
    Van de Vijver, K. K.
    Algera, M. D.
    van Der Aa, M. A.
    Sonke, G. S.
    van Driel, W. J.
    Kenter, G. G.
    Amant, F. C.
    Lok, C. A. R.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 562 - 567
  • [25] Adjuvant radiotherapy for stage I endometrial cancer (Review)
    Kong, A.
    Johnson, N.
    Cornes, P.
    Simera, I
    Collingwood, M.
    Williams, C.
    Kitchener, H.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (02):
  • [26] Incidence and Risk Factors of Lower-Extremity Lymphedema After Radical Surgery With or Without Adjuvant Radiotherapy in Patients With FIGO Stage I to Stage IIA Cervical Cancer
    Kim, Jin Hwi
    Choi, Ji Hyang
    Ki, Eun Young
    Lee, Sung Jong
    Yoon, Joo Hee
    Lee, Keun Ho
    Park, Tae Chul
    Park, Jong Sup
    Bae, Seog Nyeon
    Hur, Soo Young
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (04) : 686 - 691
  • [27] IMPROVED OVERALL SURVIVAL WITH ADJUVANT RADIOTHERAPY FOR STAGE I ENDOMETRIAL CANCER: AN ANALYSIS OF THE NATIONAL CANCER DATABASE
    Harkenrider, M.
    Adams, W.
    Block, A.
    Kliethermes, S.
    Small, W., Jr.
    Grover, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 991 - 991
  • [28] Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer
    Jeans, Elizabeth B.
    Breen, William G.
    Mullikin, Trey C.
    Looker, Brittany A.
    Mariani, Andrea
    Keeney, Gary L.
    Haddock, Michael G.
    Petersen, Ivy A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (06) : 859 - 867
  • [29] RECURRENCE OF CANCER OF THE ENDOMETRIUM AFTER COMBINED RADIATION TREATMENT
    GANINA, KP
    POLISHCHUK, LZ
    VOROBYOVA, LI
    NESINA, LP
    SKORODA, LV
    VRACHEBNOE DELO, 1990, (04): : 84 - 86
  • [30] Effect of Adjuvant Radiotherapy on Local Recurrence in Stage II Rectal Cancer
    In Ja Park
    Hee Cheol Kim
    Chang Sik Yu
    Tae Won Kim
    Se Jin Jang
    Jin Cheon Kim
    Annals of Surgical Oncology, 2008, 15 : 519 - 525